Adrian Bot
Company: Capstan Therapeutics
Job title: Founding Chief Scientific Officer & Executive Vice President - Research & development
Seminars:
Developing Safe & Efficacious Cellular Therapies For Autoimmune Disease: How Do We Ensure An Acceptable Risk-Benefit Profile? 1:00 pm
CAR-T and other cellular therapies have had huge success in the treatment of hematological malignancies; however, adverse events (AEs) including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been observed. For patients with cancer, where mortality is a real concern, these AEs are often considered an acceptable risk in the search…Read more
day: Pre-Conference Day